Amgen stock: buy or sell?
Updated on:
August 23rd, 2019
5
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology\u002Fhematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.
Should I buy Amgen stock?
Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading plan that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.Currently, Amgen stock doesn't match any of these trading strategies, so our recommendation is not to buy.
| Buy setup | Elegible |
|---|---|
| New all-time high | No |
| New 52 week high | No |
| Price crossing up 200d MA | No |
| 100d MA crossing up 200d MA | No |
Is Amgen stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.
At Stocks2.com, we gathered 15 ratings published for AMGN stock in the last 30 days. The general sentiment of these ratings is bullish for AMGN stock, with 9 positive ratings.| Date | Analyst / Broker | Previous rating | Current rating |
| 2019-8-21 | Royal Bank of Canada | n/a | Sector Perform |
| 2019-8-19 | Mizuho | Buy | Neutral |
| 2019-8-16 | Credit Suisse Group | n/a | Outperform |
| 2019-8-13 | Oppenheimer | n/a | Outperform |
| 2019-8-12 | Wells Fargo & Co | Market Perform | Positive |
| 2019-7-15 | Morgan Stanley | n/a | Overweight |
| 2019-7-1 | Mizuho | n/a | Buy |
| 2019-6-24 | Mizuho | n/a | Buy |
| 2019-5-21 | Royal Bank of Canada | n/a | Neutral |
| 2019-5-15 | JPMorgan Chase & Co. | n/a | Hold |
| 2019-4-1 | Cantor Fitzgerald | n/a | Hold |
| 2019-3-22 | Mizuho | n/a | Buy |
| 2019-3-14 | BMO Capital Markets | n/a | Outperform |
| 2019-2-26 | Cowen | n/a | Buy |
| 2019-2-13 | Mizuho | n/a | Buy |
Amgen stock analysis
Daily outlook
Amgen shares eased -2.13% to $199.08 today.
Amgen shares eased -2.13% to $199.08 today. On Aug 8th AMGN price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. For the last 14 days when SMA50d and SMA100d crossed up, AMGN price gained $15.15 per share (8.24%). On Aug 13th, AMGN hit a new all time high, pushing higher than on August 12th tops. Check different trading setups that use ATHs as triggers.
Weekly outlook
Amgen shares fell -2.42% this week, ending at $199.08. Late July AMGN rocketed an extraordinary 6.34% in just one week. Early July AMGN plunged a chilling -6.29% in just one week.
Not so far away is the last price record Amgen marked last week. Amgen stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Late July AMGN price bounced up over the SMA of 40 weeks that acted as support stopping new slides.
Amgen stock price history
Amgen IPO was on June 17th, 1983 at $0.29 per share1. Since then, AMGN stock grew a 68,548.30%, with an average of 1,904.10% per year. If you had invested right after AMGN's IPO a $1,000 in Amgen stock in 1983, it would worth $685,483.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Amgen stock historical price chart
AMGN stock reached all-time highs on Aug 13th with a price of $210.41.
Amgen stock price target is $209.90
Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We found 13 price targets for AMGN stock released in the last month:| Date | Analyst / Broker | Action | Previous target | Current target | Diff |
| 2019-8-21 | Royal Bank of Canada | Raises Target | n/a | $192.00 | - |
| 2019-8-19 | Mizuho | Downgrades | $208.00 | $212.00 | 1.9% |
| 2019-8-16 | Credit Suisse Group | Reiterates | $202.00 | $225.00 | 11.4% |
| 2019-8-13 | Oppenheimer | Raises Target | $210.00 | $230.00 | 9.5% |
| 2019-8-12 | Wells Fargo & Co | Reiterates | $197.00 | $202.00 | 2.5% |
| 2019-7-15 | Morgan Stanley | Lowers Target | $211.00 | $207.00 | -1.9% |
| 2019-7-1 | Mizuho | Reiterates | n/a | $208.00 | - |
| 2019-6-24 | Mizuho | Reiterates | n/a | $208.00 | - |
| 2019-5-21 | Royal Bank of Canada | Set Price Target | n/a | $192.00 | - |
| 2019-5-15 | JPMorgan Chase & Co. | Reiterates | n/a | $190.00 | - |
| 2019-4-1 | Cantor Fitzgerald | Reiterates | n/a | $221.00 | - |
| 2019-3-22 | Mizuho | Set Price Target | n/a | $208.00 | - |
| 2019-2-26 | Cowen | Reiterates | n/a | $234.00 | - |
| (in average) | $205.60 | $209.90 | 2.0% |
Financials and fundamental analysis
Earnings date and Earnings per Share
After posting its last earnings report on April, Amgen climbed an impressive 14.66%. Unfortunately, reported EPS is not yet available in our database.| Quarter | Reporting date | Estimated EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| 2017-Q2 | - | n/a | 2.91 | n/a |
| 2017-Q3 | 2017-10-25 | 3.11 | 3.27 | 5.1% |
| 2017-Q4 | 2018-02-01 | 3.03 | 2.89 | -4.6% |
| 2018-Q1 | 2018-04-24 | 3.23 | 3.47 | 7.4% |
| 2018-Q2 | 2018-07-26 | 3.52 | 3.83 | 8.8% |
| 2018-Q3 | 2018-10-30 | 3.42 | 3.69 | 7.9% |
| 2018-Q4 | 2019-01-29 | 3.26 | 3.42 | 4.9% |
| 2019-Q1 | 2019-04-22 | 3.48 | n/a | n/a |
| 2019-Q2 | - | n/a | n/a | n/a |
| 2019-Q3 | - | n/a | n/a | n/a |
Annual financial results
In 2018, Amgen annual revenues gained a beatiful 3.93% to $23,747.00 million USD from $22,849.00 marked in 2017. When comparing 2018 vs 2017, instead, profit margin (that is, the net income divided by revenues) climbed a 26.69% to 35.35%. Amgen fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Amgen TTM sales up to March 2019 were $23,750.00 and income $8,075.00 million dollars. If we compare this TTM figures with the last reported annuality, we can review Amgen business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, stayed steady a tight 0.01%. Regarding profit margin, Amgen declined -1.35% to 35.35%| Year | Sales | YoY | Income/(margin) | YoY |
|---|---|---|---|---|
| 2013 | $18,670 M | - | $5,080 M27.2% | - |
| 2014 | $20,063 M | 7.46% | $5,158 M25.7% | 1.54% |
| 2015 | $21,662 M | 7.97% | $6,939 M32.0% | 34.53% |
| 2016 | $22,991 M | 6.14% | $7,722 M33.6% | 11.28% |
| 2017 | $22,849 M | -0.62% | $1,979 M8.7% | -74.37% |
| 2018 | $23,747 M | 3.93% | $8,394 M35.3% | 324.15% |
| TTM | $23,750 M | 0.01% | $8,075 M34.0% | -3.80% |
Quarterly financial results
Amgen posted $5,557.00 M in sales for 2019-Q1, a -10.80% less compared to previous quarter. Reported quarter earnings marked $1,992.00 million with a profit margin of 35.85%. Profit margin appreciated a 4.90% compared to previous quarter when profit margin was 30.95%. When comparing revenues to same quarter last year, Amgen sales marked a neutral move and remained constant a 0.05%.| Quarter | Sales1 | QoQ2 | Income1/(margin) | QoQ2 |
|---|---|---|---|---|
| 2017-Q2 | $5,780 M | - | $2,150 M37.2% | - |
| 2017-Q3 | $5,780 M | 0.00% | $2,020 M34.9% | -6.05% |
| 2017-Q4 | $5,802 M | 0.38% | $-4,264 M-73.5% | -311.09% |
| 2018-Q1 | $5,554 M | -4.27% | $2,311 M41.6% | -154.20% |
| 2018-Q2 | $6,059 M | 9.09% | $2,296 M37.9% | -0.65% |
| 2018-Q3 | $5,904 M | -2.56% | $1,859 M31.5% | -19.03% |
| 2018-Q4 | $6,230 M | 5.52% | $1,928 M30.9% | 3.71% |
| 2019-Q1 | $5,557 M | -10.80% | $1,992 M35.8% | 3.32% |
Amgen ownership
When you are planning to invest in shares of a stock, it's worth to overview its ownership structure.Amgen shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.21% of all shares.
Bearish positions for AMGN stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Amgen:
| AMGN | ABBV | ALXN | BIIB | BMY | |
|---|---|---|---|---|---|
| Market cap | $121.4 B | $99.9 B | $27.7 B | $45.0 B | $78.0 B |
| Total shares | 609.9 M | 1,480.0 M | 224.3 M | 193.9 M | 1,630.0 M |
| Float shares | 598.3 M | 1,480.0 M | 223.6 M | 184.0 M | 1,630.0 M |
| - Institutional holdings (%) | 81.9% | 71.9% | 96.8% | 93.4% | 75.0% |
| - Insider holdings (%) | 0.2% | 0.1% | 0.3% | 0.5% | 0.1% |
| Shares in short selling | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Amgen summary
| Friday, August 23rd, 2019 | |
|---|---|
| Open | $203.09 |
| Close | $199.08 |
| Day range | $198.01 - $203.62 |
| Previous close | $203.42 |
| Session gain | -2.13% |
| Average true range | $6.14 |
| 50d mov avg | $184.84 |
| 100d mov avg | $180.19 |
| 200d mov avg | $184.01 |
| Daily pattern | lt01a |
| Weekly pattern | lt06a |
Amgen performance
Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. In the following table, we compare Amgen to AbbVie, Alexion Pharmaceuticals, Biogen, Bristol-Myers Squibb, Celgene, Gilead Sciences, GlaxoSmithKline, and Pfizer:| Stock | 3m | 6m | 12m |
|---|---|---|---|
| AMGNAmgen | 17.05% | 7.85% | 4.36% |
| ABBVAbbVie | -14.38% | -13.20% | -27.04% |
| ALXNAlexion Pharmaceu... | -2.79% | -4.81% | 5.10% |
| BIIBBiogen | 2.20% | -28.67% | -32.21% |
| BMYBristol-Myers Squ... | 3.15% | -4.45% | -17.61% |
| CELGCelgene | 0.49% | 7.37% | 6.43% |
| GILDGilead Sciences | -3.08% | -0.43% | -9.60% |
| GSKGlaxoSmithKline | 3.70% | 3.99% | 4.92% |
| JNJ | -5.46% | -2.60% | -0.86% |
| PFEPfizer | -15.59% | -16.85% | -14.36% |
Amgen competitors
One check before trading any stock is to have a look a list of its competitors, in this case for Amgen. We picked 9 companies as Amgen competitors as they are in the same industry or have similar market objectives.- AbbVie (ABBV)
- Alexion Pharmaceuticals (ALXN)
- Biogen (BIIB)
- Bristol-Myers Squibb (BMY)
- Celgene (CELG)
- Gilead Sciences (GILD)
- GlaxoSmithKline (GSK)
- (JNJ)
- Pfizer (PFE)
Latest Amgen stock news
- Seeking AlphaMirati's Stock Gaps Higher On Amgen's Data, Opens Up Massive OpportunityJune 6, 2019
- Seeking AlphaAmgen Breaches Hurdle For Decades Of Research To Bring A New Drug To RealityJune 6, 2019
- InvestorPlaceAmgen Earnings: AMGN Stock Dips Slightly Despite Q1 EPS, Sales BeatApril 30, 2019
- Seeking AlphaAmgen Evenity Approval Just Makes It A HoldApril 18, 2019
- InvestorPlace3 Big Stock Charts for Thursday: Citrix Systems, Goldman Sachs Group and AmgenApril 18, 2019